Treatment of Protein S Deficiency
For patients with protein S deficiency who develop venous thromboembolism (VTE), anticoagulation with either low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) is the primary treatment, with DOACs increasingly preferred for their convenience and predictable pharmacokinetics.
Acute VTE Management
When protein S deficiency presents with acute VTE, initiate anticoagulation immediately:
- Start with LMWH or unfractionated heparin (UFH) for at least 5 days 1
- Transition to long-term anticoagulation can begin as early as day 1, with discontinuation of heparin after day 6 once therapeutic levels are achieved 1
Long-Term Anticoagulation Options
Direct Oral Anticoagulants (DOACs)
DOACs are routinely used for protein S deficiency despite lack of randomized trials, with evidence showing reduced bleeding events and low VTE recurrence 2. The 2026 ACC guidelines specifically note that DOACs are a good option for most patients with thrombophilia, including protein S deficiency 2.
Specific DOAC evidence:
- Rivaroxaban has demonstrated efficacy in multiple case reports for protein S deficiency, including warfarin-refractory cases 3, 4, 5, 6
- Apixaban is also used, with recent data suggesting it may be superior to rivaroxaban due to lower bleeding risk 2
Vitamin K Antagonists (Warfarin)
Warfarin remains an option but has significant limitations:
- Requires INR monitoring with target 2.0-3.0 7
- Critical caveat: In severe protein S deficiency, warfarin can paradoxically cause skin necrosis by reducing protein C levels before reducing procoagulant factors 8, 6
- If warfarin-induced skin necrosis occurs, switch to a DOAC (rivaroxaban has proven effective) 6
Duration of Anticoagulation
The duration depends on VTE characteristics:
- Provoked VTE (with reversible risk factor): 3 months minimum 1
- Unprovoked VTE: 6-12 months minimum 1
- Recurrent VTE: Indefinite anticoagulation 1
- High-risk thrombophilia (protein S deficiency with other thrombophilic defects): Consider indefinite therapy 9, 10
The 2026 ACC guidelines support extended treatment beyond 6 months for unprovoked VTE and those with high recurrence risk profiles 2.
Special Populations
Pregnancy
Pregnant women with protein S deficiency require specific management 11:
- Antepartum: Use prophylactic LMWH if there is a family history of VTE (conditional recommendation)
- Postpartum: Prophylactic LMWH for 6 weeks is recommended regardless of family history
- Avoid warfarin in first trimester (teratogenic) and last 6 weeks (bleeding risk) 7
Neonates with Severe Deficiency
For homozygous protein S deficiency presenting as purpura fulminans:
- Immediate fresh frozen plasma (10-20 mL/kg every 12 hours) or protein S concentrate if available 1
- Long-term options include LMWH, warfarin, or liver transplantation 1
Monitoring and Dose Adjustments
For DOACs in protein S deficiency:
- Recent evidence suggests reduced-dose DOACs may have higher VTE recurrence rates (8.1 per 100 patient-years) compared to full-dose therapy 10
- Recommendation: Maintain full therapeutic doses rather than prophylactic doses for secondary prevention
Important consideration: Protein S deficiency combined with other thrombophilic defects significantly increases recurrence risk and warrants more aggressive anticoagulation 10.
Key Clinical Pitfalls
- Do not assume warfarin is safe in severe protein S deficiency - it can cause skin necrosis through protein C depletion 8, 6
- Avoid premature dose reduction of DOACs - full therapeutic doses are more effective for preventing recurrence 10
- Screen for concurrent thrombophilias - combined defects dramatically increase risk and may require indefinite anticoagulation 9, 10
- Consider quality of life factors - protein S deficiency patients have high rates of CNS-active medication use (33%), suggesting significant disease burden 10